Silence Therapeutics Plc2024财年实现净利润-45.33百万美元，同比增加15.71%

市场透视2025-03-08

3月8日，Silence Therapeutics Plc（SLN.US）公布财报，公告显示公司2024财年净利润为-45.33百万美元，同比增加15.71%；其中营业收入为43.28百万美元，同比增加37.22%，每股基本收益为-0.98美元。从资产负债表来看，Silence Therapeutics Plc（SLN.US）总负债68.61百万美元，其中短期债务117000.00美元，资产负债...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517458291?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-08 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2517458291","market":"us","top_or_hot":-1,"title":"Silence Therapeutics Plc2024财年实现净利润-45.33百万美元，同比增加15.71%","media":"市场透视","content":"<div>\n<p>3月8日，Silence Therapeutics Plc（SLN.US）公布财报，公告显示公司2024财年净利润为-45.33百万美元，同比增加15.71%；其中营业收入为43.28百万美元，同比增加37.22%，每股基本收益为-0.98美元。从资产负债表来看，Silence Therapeutics Plc（SLN.US）总负债68.61百万美元，其中短期债务117000.00美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000124a2647e9b&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Silence Therapeutics Plc2024财年实现净利润-45.33百万美元，同比增加15.71%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSilence Therapeutics Plc2024财年实现净利润-45.33百万美元，同比增加15.71%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-08 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000124a2647e9b&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3月8日，Silence Therapeutics Plc（SLN.US）公布财报，公告显示公司2024财年净利润为-45.33百万美元，同比增加15.71%；其中营业收入为43.28百万美元，同比增加37.22%，每股基本收益为-0.98美元。从资产负债表来看，Silence Therapeutics Plc（SLN.US）总负债68.61百万美元，其中短期债务117000.00美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000124a2647e9b&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000124a2647e9b&s=b","article_id":"2517458291","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250308000124a2647e9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2517458291","pubTimestamp":1741363242,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"3月8日，Silence Therapeutics Plc公布财报，公告显示公司2024财年净利润为-45.33百万美元，同比增加15.71%；其中营业收入为43.28百万美元，同比增加37.22%，每股基本收益为-0.98美元。从资产负债表来看，Silence Therapeutics Plc总负债68.61百万美元，其中短期债务117000.00美元，资产负债比为0.03，流动比率为0.12。机构评级：截至2025年3月8日，当前有6家机构对Silence Therapeutics Plc目标价做出预测，其中目标均价为39.76美元，其中最低目标价为4.06美元，最高目标价为77.77美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","SLN":"Silence Therapeutics Plc"},"translate_title":"Silence Therapeutics Plc achieved net profits of-US $45.33 million in fiscal year 2024, a year-on-year increase of 15.71%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":0.6,"SLN":0.6},"content_text":"3月8日，Silence Therapeutics Plc（SLN.US）公布财报，公告显示公司2024财年净利润为-45.33百万美元，同比增加15.71%；其中营业收入为43.28百万美元，同比增加37.22%，每股基本收益为-0.98美元。从资产负债表来看，Silence Therapeutics Plc（SLN.US）总负债68.61百万美元，其中短期债务117000.00美元，资产负债比为0.03，流动比率为0.12。机构评级：截至2025年3月8日，当前有6家机构对Silence Therapeutics Plc目标价做出预测，其中目标均价为39.76美元，其中最低目标价为4.06美元，最高目标价为77.77美元。公司简介：Silence Therapeutics PLC是一家专注于发现和开发含有短干扰核糖核酸的新分子的生物技术公司。公司管道产品有;SLN360疗法旨在暂时阻断可能引发不良影响的特定基因信息。通过沉默LPA基因，降低Lp(a)的水平，这反过来有望降低心脏病、心脏病发作和中风的风险，而SLN124疗法旨在暂时沉默TMPRSS6，一种阻止肝脏产生控制体内铁调素铁水平的特定激素的基因。随着hepcidin的增加，血液中的铁含量预计会降低，这可能会产生更多健康的红细胞，从而减少贫血。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517458291","isCrawlerRequest":true}